Arena Pharmaceuticals (ARNA) today reported that its Tokyo based partner Eisai, has been able to secure improved patient access of the company’s weight-loss drug, Belviq with two leading managed healthcare benefit companies, CVS Caremark (CVS) and Aetna (AET). The company’s stock price jumped 7% on the news to close at $6.43 yesterday. The company announced that Eisai has signed an agreement with pharmacy benefits manager, CVS Caremark (CVS) to make Arena’s recently developed weight loss drug, Belviq available in its pharmacies.
Source:
http://ift.tt/1rOfwjT